Radiochemistry for the Pharmacokinetic Evaluation of Novel Bone-Targeting Peptide Hormone Derivatives

This proposed research project is about development of new bone-targeting drug called PTHPEG- BP, this new compound will overcome shortages of current clinical peptide hormone PTH, and show better treatment efficacy and lower price then the latter; several new technologies will be used on research of this PTH, such as micro Positron Emission Tomography (PET/CT), and several of its characteristics will be identified such as structure, bioactivity, and metabolism inside body. After preparation of this compound, its production will be scaled up for commercialization by our partner organization Osteometabolix Pharmaceuticals Inc., which in collaboration with big Pharma, will undertake clinical trials of PTH-PEG-BP in human patients; our ultimate goal is to develop PTH-PEG-BP towards investigational new drug (IND) status.

Faculty Supervisor:

Mike Doschak

Student:

Partner:

Osteometabolix Pharmaceuticals Inc;University of Alberta

Discipline:

Life Sciences

Sector:

Education; Health and Related Sciences & Technology

University:

University of Alberta

Program: